2020 (v1)
Journal article
International audience
Uploaded on: December 3, 2022
-
-
2017 (v1)Journal article
67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) - Boston, MA - 2016-11-11
Uploaded on: February 28, 2023 -
March 19, 2018 (v1)Journal article
Background: Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral (DAA)–based regimens is commonly associated with emergence of resistance-associated substitutions (RASs). Retreatment of patients who failed prior DAAs remains challenging. The aim of this prospective and randomized study was...
Uploaded on: February 27, 2023 -
September 2013 (v1)Journal article
Background & AimsIn phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced cirrhotic and non-cirrhotic patients, but few cirrhotics were included. We report the week 16 safety and efficacy analysis in a cohort of compensated...
Uploaded on: February 28, 2023 -
July 2014 (v1)Journal article
BACKGROUND & AIMS: We investigated the effectiveness of the protease inhibitors peginterferon and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 infection and cirrhosis. METHODS: In the Compassionate Use of Protease Inhibitors in Viral C Cirrhosis study, 511 patients with HCV genotype 1 infection and...
Uploaded on: March 25, 2023 -
August 2019 (v1)Journal article
International audience
Uploaded on: December 4, 2022